CLSD Clearside Biomedical Inc

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022:

BTIG Ophthalmology Day

Fireside Chat

Tuesday, November 29, 2022 at 10:30 a.m. ET

Piper Sandler 34th Annual Healthcare Conference

Corporate Presentation

Thursday, December 1, 2022 at 9:50 a.m. ET

Ophthalmology Innovation Summit (OIS) XII

Panel Discussion: Spotlight on Gene & Cell Therapy

Retina Innovation Showcase: Corporate Presentation

Saturday, December 3, 2022

Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Ophthalmology Panel Discussion: Take A Look At What's In Store For Wet AMD & Related Diabetic Eye Diseases

Thursday, December 8, 2022 at 2:45 p.m. ET

A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: .

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit .

Investor and Media Contacts:



Jenny Kobin

Remy Bernarda



(678) 430-8206

Source: Clearside Biomedical, Inc.



EN
22/11/2022

Underlying

CLSDClearside Biomedical Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clearside Biomedical Inc

 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Trea...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has...

July 23, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Plan to Explore Strategic Alternatives ...

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, G...

July 17, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces Multiple Presentations to be Featured a...

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), a...

June 17, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2...

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors sectio...

May 21, 2025 1 EN
 PRESS RELEASE
Free
CLSD Clearside Biome...

Clearside Biomedical Announces First Quarter 2025 Financial Results an...

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Development Partners - - Use of Suprachoroidal Drug Delivery Featured in Over 15 Presentations at Major Ophthalmic Medical Meetings This Year - ALPHARETTA, Ga., May 14, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CLSD), a biophar...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch